| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 3.405.749 | 4.391.722 | 5.682.973 | 6.380.261 | 7.505.741 | 6.395.515 | 8.917.420 | 10.229.949 | 10.248.606 | 9.876.196 |
| Total Income - EUR | 3.608.497 | 4.589.895 | 5.886.687 | 6.493.019 | 7.724.940 | 6.412.014 | 9.069.977 | 10.676.771 | 10.054.476 | 9.431.165 |
| Total Expenses - EUR | 3.758.999 | 4.441.467 | 5.768.549 | 6.109.752 | 7.600.754 | 6.172.577 | 8.909.251 | 9.717.346 | 10.074.700 | 9.290.958 |
| Gross Profit/Loss - EUR | -150.502 | 148.428 | 118.138 | 383.267 | 124.187 | 239.437 | 160.727 | 959.424 | -20.224 | 140.207 |
| Net Profit/Loss - EUR | -150.502 | 108.763 | 70.386 | 366.412 | 94.783 | 198.229 | 117.158 | 838.691 | -45.158 | 99.200 |
| Employees | 76 | 82 | 98 | 99 | 99 | 84 | 82 | 87 | 91 | 96 |
Check the financial reports for the company - Hyllan Pharma Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 462.180 | 380.097 | 563.348 | 771.474 | 622.519 | 408.626 | 560.159 | 350.072 | 750.026 | 697.797 |
| Current Assets | 1.737.098 | 1.922.656 | 2.100.330 | 2.729.995 | 3.201.080 | 2.970.747 | 4.142.969 | 4.184.708 | 4.890.106 | 4.542.783 |
| Inventories | 623.241 | 739.077 | 821.216 | 862.941 | 988.539 | 896.228 | 1.482.674 | 1.355.320 | 912.349 | 1.173.887 |
| Receivables | 951.758 | 972.724 | 1.114.242 | 1.795.118 | 2.136.719 | 1.721.125 | 2.489.283 | 2.767.424 | 3.306.869 | 3.321.825 |
| Cash | 162.099 | 210.855 | 164.872 | 71.937 | 75.822 | 353.393 | 171.012 | 61.964 | 670.888 | 47.071 |
| Shareholders Funds | -570.865 | -457.107 | 372.376 | 701.125 | 782.330 | 965.728 | 1.061.469 | 1.903.454 | 1.852.524 | 1.941.370 |
| Social Capital | 15.231 | 15.075 | 766.183 | 752.122 | 737.556 | 723.574 | 707.528 | 709.723 | 707.571 | 703.617 |
| Debts | 2.774.744 | 2.765.876 | 2.343.134 | 2.798.087 | 3.043.471 | 2.374.089 | 3.599.223 | 2.627.619 | 3.770.586 | 3.312.507 |
| Income in Advance | 0 | 0 | 0 | 1.102 | 7.994 | 26.112 | 25.361 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4638 - 4638" | |||||||||
| CAEN Financial Year |
1089
|
|||||||||
Comments - Hyllan Pharma Srl